NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
Status:
Not yet recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to compare short-term Triple Antithrombotic Therapy (DAPT
+ Rivaroxaban) followed by DAPT with standard DAPT in selected ACS patients with high
ischemic risk. The main questions it aims to answer are:
- Whether the intervention is effective in reducing ischemic events
- Whether the intervention is safe from increasing bleeding events, especially severe or
fatal ones
Participants will be randomized to receive standard DAPT therapy for the entire study
duration or low-dose rivaroxaban+DAPT for 3 months, followed by standard DAPT for the rest of
the study duration. Patients enrolled should complete 5 follow-ups in the form of clinic
visit or telephone call.